A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) (NCT05920356)
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
🩺 Plain-English Summary (8th-Grade Level)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Sansum Clinic — Santa Barbara, California
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (414 Sites)
Showing the first 25 of 414 sites.
- Sansum Clinic — Santa Barbara, California
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center — Newark, Delaware
- Florida Clinical Trials Group Plantation — Plantation, Florida
- Florida Clinical Trials Group Tamarac — Tamarac, Florida
- University of Illinois Chicago — Chicago, Illinois
- Illinois Cancer Specialists — Niles, Illinois
- Norton Cancer Institute - Brownsboro — Louisville, Kentucky
- Reliant Medical Group Inc — Worcester, Massachusetts
- University of New Mexico Cancer Center — Albuquerque, New Mexico
- Memorial Sloan Kettering Cancer Center — New York, New York
- Messino Cancer Centers Asheville — Asheville, North Carolina
- Duke University Medical Center — Durham, North Carolina
- FirstHealth Cancer Center — Pinehurst, North Carolina
- Dayton Physician's Network — Dayton, Ohio
- Alliance Cancer Specialists - Media — Media, Pennsylvania
- University of Pittsburgh Medical Center Hillman Cancer Center — Pittsburgh, Pennsylvania
- University of Tennessee Medical Center Knoxville — Knoxville, Tennessee
- Regional One Health — Memphis, Tennessee
- Sarah Cannon Research Institute — Nashville, Tennessee
- United States Oncology Regulatory Affairs Corporate Office — Nashville, Tennessee
- Oncology Consultants PA — Houston, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- US Oncology Research Investigational Products Center — Irving, Texas
- Vista Oncology Inc PS — Olympia, Washington
- Mercyhealth — Janesville, Wisconsin
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-Small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.